Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients
Purpose. Denosumab is a monoclonal antibody that prevents the development of osteoclasts. The effect of denosumab in solid organ transplant recipients has been elucidated, but its effect in haematopoietic stem cell transplantation recipients has not been studied yet. The aim of this study was to det...
Saved in:
Main Authors: | Chaiho Jeong, Hee-Je Kim, Seok Lee, Moo Il Kang, Jeonghoon Ha |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2020/3410921 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Effects of Noncompliance to Prolia (Denosumab) on the Changes in Bone Mineral Density: A Retrospective Review
by: Matthew Wong-Pack, et al.
Published: (2016-01-01) -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
by: José Luis Piñana, et al.
Published: (2024-08-01) -
Left ventricular remodeling and its association with mineral and bone disorder in kidney transplant recipients
by: Li Sun, et al.
Published: (2024-12-01) -
Monocyte‐predominant engraftment, cytokine levels and early transplant‐related complications in pediatric hematopoietic stem cell recipients
by: Natalia Maximova, et al.
Published: (2019-03-01) -
Genome-Wide Association Study of Bone Mineral Density in Korean Men
by: Ye Seul Bae, et al.
Published: (2016-06-01)